摘要
目的:研究布拉氏酵母菌散治疗急性感染性腹泻(AID)患儿的临床疗效,并评价其对患儿症状改善及血清炎性因子水平的影响。方法:选取2017年4月至2019年4月于我院治疗的AID患儿160例进行研究,并按照患者病历号使用单双号法分为观察组(单号)与对照组(双号),各组80例;在常规措施基础上,对照组给予蒙脱石散治疗,观察组给予布拉氏酵母菌散联合蒙脱石散治疗,疗程为一周。比较两组患儿治疗有效率、症状改善情况、大便次数及性状、血清炎症指标[白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、超敏C反应蛋白(hs-CRP)、干扰素-γ(INF-γ)]水平及不良反应发生情况。结果:治疗后,观察组治疗有效率为92.50%,显著高于对照组80.00%(P<0.05)。观察组患儿腹痛、呕吐、止泻消失时间及住院时间显著低于对照组(P<0.05)。治疗后,两组患儿大便次数、大便性状评分、IL-6、TNF-α、hs-CRP、INF-γ较治疗前显著降低(P<0.05),且观察组上述指标与同期对照组对比差异显著(P<0.05)。治疗期间,两组患儿不良反应发生率差异无统计学意义(P>0.05)。结论:布拉氏酵母菌散治疗急性感染性腹泻患儿临床疗效显著,能有效改善患儿症状,降低炎性反应,安全性好,具有临床较好的应用价值。
Objective:To study the clinical efficacy of saccharomyces boulardii in the treatment of children with acute infectious diarrhea(AID),and to evaluate its effects on symptom improvement and serum inflammatory factors.Methods:160 children patients with AID treated in our hospital from April 2017 to April 2019 were selected for the study,and the patients were divided into observation group(odd medical record numbers)and control group(even medical record numbers)using a odd-even number method,with 80 cases in each group.On the basis of routine measures,control group was administrated montmorillonite powder,and observation group was administrated saccharomyces boulardii combined with montmorillonite powder,and they were treated for one week.The effective rate of treatment,symptom improvement,stool frequency traits,intestinal microbial condition,levels of serum inflammatory indexes[interleukin-6(IL-6),tumor necrosis factor-α(TNF-α),hypersensitive C-reactive protein(hs-CRP),interferon-γ(INF-γ)]and occurrence of adverse reactions were compared between the two groups.Results:The effective rate of treatment in observation group was significantly higher than that in control group(92.50%vs 80.00%)(P<0.05).The disappearance times of abdominal pain,vomiting and diarrhea and hospital stay in observation group were significantly lower than those in control group(P<0.05).After treatment,the stool frequency,stool trait score,and levels of IL-6,TNF-α,hs-CRP and INF-γin the two groups were significantly decreased compared with those before treatment,while the quantity of bacteroides was significantly increased(P<0.05),and the above indexes in observation group were significantly different from those in control group at the same time point(P<0.05).There was no significant difference in incidence rate of adverse reactions between the two groups during treatment(P>0.05).Conclusion:Saccharomyces boulardii has significant clinical efficacy in the treatment of acute infectious diarrhea,and it can effectively improve the symptoms,and reduce the inflammatory response,with good safety and good clinical application value.
作者
陈丹丹
尹杨艳
桂冬梅
CHEN Dandan;YIN Yangyan;GUI Dongmei(The First Affiliated Hospital of Hainan Medical College,Hainan Haikou 570100,China)
出处
《河北医学》
CAS
2021年第2期330-334,共5页
Hebei Medicine
基金
海南省卫生计生行业基金项目,(编号:16A200012)。
关键词
布拉氏酵母菌散
急性感染性腹泻
炎性因子
Saccharomyces boulardii
Acute infectious diarrhea
Inflammatory factors
